Adrogolide Hydrochloride
Adrogolide Hydrochloride has been in phase II clinical trials for the treatment of Parkinson's disease (PD) and cocaine abuse. However, this research has been discontinued.
This compound was originally discovered by Abbott, then licensed to DrugAbuse Sciences.
General Information
Update Date：2016-04-22
- Drug Name：
- Adrogolide Hydrochloride
- Research Code：
- A-93431.1; ABT-431; DAS-431
- Trade Name：
- MOA：
- Dopamine receptor D1 agonist
- Indication：
- Parkinson's disease (PD); Cocaine abuse
- Status：
- Phase Ⅱ (Discontinued)
- Company：
- Abbott (Originator) , DrugAbuse Sciences
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-02-03
|
Molecular Weight | 435.96 | ||||||||||||
| Formula | C22H25NO4S • HCl | |||||||||||||
| CAS No. |
171752-56-0 (Adrogolide); 166591-11-3 (Adrogolide hydrochloride); |
|||||||||||||
| Chemical Name | Benzo[f]thieno[2,3-c]quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-, 9,10-diacetate, hydrochloride (1:1), (5aR,11bS)- | |||||||||||||
| Adrogolide （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||